Primary Biliary Cholangitis - A New Name and a New Treatment.
N Engl J Med. 2016 Aug 18;375(7):685-687
Authors: Pratt DS
Primary biliary cholangitis, previously called primary biliary cirrhosis, is a cholestatic autoimmune liver disease that is marked by the progressive lymphocytic destruction of the smallest intralobular bile ducts.(1),(2) In the absence of effective therapy, it progresses inexorably to cirrhosis and liver failure. Ursodiol, a hydrophilic bile acid with an excellent safety profile, was approved by the Food and Drug Administration (FDA) in 1988 for the dissolution of gallstones. On the basis of early promising data in the management of primary biliary cholangitis and the unmet clinical need, the FDA granted ursodiol orphan status in 1991 for the management of . . .
PMID: 27532836 [PubMed - as supplied by publisher]